Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus concurrent chemoradiotherapy in high-risk or ctDNA-positive postoperative head and neck squamous cell carcinoma (Phase II)
ChiCTR2200066336Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by First Hospital of China Medical University. Primary endpoints: Progression-free survival (disease-free survival) and Safety. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200066336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066336.